Original Article

Investigating Visfatin gene Polymorphism rs4730153 with Insulin Resistance and Non-Alcoholic Fatty Liver Diseases in Iranian Population

Abstract

Background: Visfatin is known as one of the adipokines associated with the development of inflammation, but its role in the pathogenesis of nonalcoholic fatty liver is less known so far. We aimed to investigate the association between visfatin gene polymorphism rs4730153 and insulin resistance and non-alcoholic fatty liver disease (NAFLD).

Methods: This case-control study was performed on 80 patients with NAFLD as well as 80 healthy participants as controls referred to Amir Al-Momenin and Bouali hospitals in Tehran. Genotyping was performed using PCR-RFLP method. Plasma concentrations of visfatin and insulin were measured using ELISA kit. The fasting blood glucose, TC, TG, LDL-C, HDL-C, ALT, AST, SBP, DBP, and BMI levels were measured using the standard methods. Statistical analysis was also performed using SPSS software.

Results: A significant difference was found in Visfatin level in the patients with NAFLD compared to this level in healthy individuals. The levels of HDL-C and LDL-C in healthy individuals and triglyceride in patients for GG, AG, and AA genotypes carriers also were significantly different. There was a significant relationship between rs4730153 polymorphism and insulin resistance; however, no association was found between this polymorphism and NAFLD. Notably, Visfatin showed a significant association with age (all individuals), body mass index (healthy individuals), insulin, and HOMA (in patients).

Conclusion: Visfatin levels reduced in patients with NAFLD. Moreover, rs4730153 polymorphism was indicated to be associated with both lipid metabolism and insulin resistance, but no association was found between this polymorphism and nonalcoholic fatty liver disease.

1. Rahmani R, Nezhadali M, Rastegar Moghaddam J (2019). Association of ad-iponectin level with biochemical variables and insulin resistance in patients with non-alcoholic fatty liver disease in an Ira-nian population. Medical Science, 29(4): 329-336.
2. Liu HW, Liu JS, Kuo KL (2019). Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cas-es from health checkup center in Taiwan. Ci Ji Yi Xue Za Zhi, 32(1):65-69.
3. Rezaie F, Nezhadali M, Hedayati M (2018). Association of adiponectin rs17300539 gene polymorphism with a nonalcoholic fatty liver disease in an Iranian popula-tion. Feyz, 22)4(: 379-386. (Persian)
4. Pandey AK, Jalihal U, Pramila Mn, et al. (2015). Estimation of adiponectin levels in diabetic, non-diabetic fatty liver diseas-es and healthy controls. Int J Res Med Sci, 3(1): 140-146.
5. Sun C, Fan J-G1, Qiao L (2015). Potential Epigenetic Mechanism in Non-Alcoholic FattyLiver Disease. Int J Mol Sci,16(3): 5161–5179.
6. Salama HM, Galal A, Motawie AA, et al. (2015). Adipokines Vaspin and Visfatin in Obese Children. Open Access Maced J Med Sci, 3(4):563-6.
7. Mousavi Z, Ganji A, Farrokh Tehrani D, et al. (2017). Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome. Med J Islam Repub Iran, 31:28.
8. Genc H, Dogru T, Kara M, et al. (2013). As-sociation of plasma visfatin with hepatic and systemic inflammation in nonalco-holic fatty liver disease. Ann Hepatol, 12(4): 548-55.
9. Nourbakhsh M, Nourbakhsh M, Gholinejad Z, et al. (2015). Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scand J Clin Lab In-vest, 75(2): 183–188.
10. Kamińska A, Kopczyńska E, Bronisz A, et al. (2010). An evolution of visfatin levels in obese subjects. Endokrynol Pol, 61(2):169-173.
11. Mageswari R, Sridhar MG, Nandeesha H, et al. (2019). Irisin and Visfatin Predicts Se-verity of Diabetic Nephropathy. Indian J Clin Biochem, 34(3):342–346.
12. Jahani F, Khazaei Z, Moodi M, et al. (2020). The relation of visfatin with nausea and vomiting in the pregnancy. J Res Med Sci, 25:80.
13. AL-Suhaimi EA, Shehzad A (2013). Leptin, resistin and visfatin: the missing link be-tween endocrine metabolic disorders and immunity. Eur J Med Res, 8(1): 12.
14. Saddi-Rosa P, Oliveira CSV, Giuffrida FMA, et al. (2010). Visfatin, glucose metabolism and vascular disease: a review of evi-dence. Diabetol Metab Syndr, 2:21.
15. Fukuhara A, Matsuda M, Nishizawa M, et al. (2005). Visfatin: a protein secreted by vis-ceral fat that mimics the effects of insulin. Science, 307(5708): 426-430.
16. Ozgocmen M, Gokcimen A, Oncu M, et al. (2018). Effects of Non-Alcoholic Fatty Liver Disease on Visfatin and IL-6 Lev-els in Mice: An Immunohistochemical Study. Immunochem Immunopathol, 4:131.
17. Haghjooy Javanmard S, Dehghananzadeh R, Rafiee L, et al. (2016). Genetic associa-tions of the visfatin G 948T polymor-phism with obesity related metabolic traits in an Iranian population. J Res Med Sci, 21:105.
18. Jin LW, Zheng SB, Zhou ZH, et al. (2016). Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification. Genet Mol Res, 15 (2): 10.4238/gmr.15028217.
19. Lai A, Chen W, Helm K (2013). Effects of Visfatin gene Polymorphism rs4730153 on Exercise- induced weight loss of obese children and adolescents of Han Chinese. Int J Biol Sci, 9(1):16-21.
20. Vasilache SL, Mărginean CO, Boaghi A, et al. (2020). Implications of visfatin genetic variants in the metabolic profile of the Romanian pediatric population. Rev Rom Med Lab, 28(2): 163-174.
21. Al-Harithy RN (2014). Common polymor-phisms in the visfatin gene (NAMPT/PBEF1) influence visfatin-circulating levels in a Saudi population. Life Sci,11(10):205-210.
22. Ashoori M, Nezhadali M, Shiehmorteza M (2018). The relationship between visfatin levels and Anthropometric parameters and insulin resistance in women with prediabetes and type 2 diabetes. Yafte, 20(3):9-18.
23. Papi A, Nezhadali M, Alinezhad M (2018). Relationship of serum visfatin level in obese individuals with insulin and body mass index. Journal of Police Medicine, 7(4):161-165.
24. Ihsan I, Rini EA, Yaswir R (2016). Visfatin levels in non-obese, obese, and insulin resistant adolescents. Paediatrica Indone-siana, 56(5): 291-296.
25. Baltaci D, Tuncel MC, Cetinkaya M, et al. (2016). Evaluation of Visfatin in Patients with Obesity, Metabolic Syndrome, Insu-lin Resistance and Impaired Glucose Tol-erance; Case-Control Study. Acta Medica Anatolia, 4(2): 61-67.
26. Ożegowska K, Bartkowiak-Wieczorek J, Bo-gacz A (2020). Relationship between adi-pocytokines and angiotensin converting enzyme gene insertion/deletion poly-morphism in lean women with and with-out polycystic ovary syndrome. Gynecol Endocrinol, 36(6): 496-500.

27. Ferrari GD, Rodrigues JAL, Fernandes LA, et al. (2016). Association between rs4730153 Gene SNP and fasting Glu-cose, triglyceride, HDL and body Mass Index Levels Iin Overweight Brazilian Adults. Int J Cardiovasc Sci, 29(6):471-476.
Files
IssueVol 51 No 5 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v51i5.9429
Keywords
Visfatin Insulin Resistance NAFLD rs4730153
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Marjani S, Nezhadali M, Hekmat A, Zarif Yeganeh M. Investigating Visfatin gene Polymorphism rs4730153 with Insulin Resistance and Non-Alcoholic Fatty Liver Diseases in Iranian Population. Iran J Public Health. 2022;51(5):1143-1151.